MedTrace Logo

Prospective Study to Assess a Diagnostic Aid for Cancer

NCT07046260 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1650

Last updated 2026-03-11

No results posted yet for this study

Summary

The primary objective of this study is to establish the performance of two blood-based diagnostic aid test for cancer detection in individuals presenting with symptoms, signs, or findings suggestive of cancer.

Conditions

Interventions

OTHER

Blood sample collection

The study will collect up to 40 mL of whole peripheral blood in Streck Cell-Free DNA BCT® tubes from each participant.

Sponsors & Collaborators

  • Harbinger Health

    lead INDUSTRY

Principal Investigators

  • Luke Pike, MD, DPhil · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-11
Primary Completion
2026-07-31
Completion
2026-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07046260 on ClinicalTrials.gov